Please assess the completion status of the following clinical trial:

Trial Title: Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ambulatory adults aged 50 and older.~2. Medically stable, as determined by medical history and targeted physical examination. Medically stable is defined as no change in diagnoses or chronic medications (dose or class) for medical reasons in the 3 months prior to study.~3. Absence of underlying conditions that make participation in the study contrary to the subject's best interest.~4. Able to understand and comply with planned study procedures.~5. Provides written informed consent prior to initiation of any study procedure.~Exclusion Criteria:~1. Known contraindication to either study vaccine (see product package inserts)~2. Receipt of any other influenza vaccine within 180 days prior to enrollment in this study.~3. Underlying disease or ongoing therapy that might cause immunocompromise, e.g. cytotoxic agents or supraphysiologic doses of corticosteroids, such that response to vaccination might be sub-optimal.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Flublok Quadrivalent Influenza Vaccine (Type: EXPERIMENTAL): Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
- Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).